Prevention and Treatment of Cardiovascular Disease

Prevention and Treatment of Cardiovascular Disease
Author: Michael J. Wilkinson
Publisher: Springer Nature
Total Pages: 279
Release: 2021-08-13
Genre: Medical
ISBN: 3030781771

This book discusses all aspects of non-pharmacologic approaches to primary and secondary CVD prevention. It highlights the strength of evidence for particular diet styles in CVD prevention, including plant-based diets, the Mediterranean diet, the DASH diet, and low-carbohydrate diets. Chapters present evidence and future directions for diet and nutrition in diseases related to CVD, such as dyslipidemia, cardiometabolic disease (pre-diabetes, the metabolic syndrome, type-2 diabetes mellitus), and obesity. Finally, the book reviews novel and emerging aspects of dietary intervention in CVD prevention, such as dietary approaches to inflammation and the role of the microbiome in CVD. Up-to-date, evidence-based, and clinically oriented, Prevention and Treatment of Cardiovascular Disease: Nutritional and Dietary Approaches is an essential resource for physicians, residents, fellows, and medical students in cardiology, clinical nutrition, family medicine, endocrinology, and lipidology.

Lipids and Atherosclerosis

Lipids and Atherosclerosis
Author: Chris J. Packard
Publisher: CRC Press
Total Pages: 311
Release: 2005-09-08
Genre: Medical
ISBN: 1135401322

New discoveries in genetics, molecular, and cell biology are not only enhancing our understanding of the etiology and progression of disease, but are finding applications in the development of new drugs or the implementation of new kinds of therapy. This book provides an in-depth review of emerging areas in biomedical research at the interface of s

A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases

A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases
Author: Institute of Medicine
Publisher: National Academies Press
Total Pages: 200
Release: 2011-08-26
Genre: Medical
ISBN: 0309212197

Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data-including population surveys, cohort studies, disease registries, administrative health data, and vital statistics-contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.

Coronary Vasomotion Abnormalities

Coronary Vasomotion Abnormalities
Author: Hiroaki Shimokawa
Publisher: Springer Nature
Total Pages: 155
Release: 2020-12-08
Genre: Medical
ISBN: 9811575940

This book reviews the latest findings on epicardial coronary spasm and coronary microvascular dysfunction (CMD), important diseases for understanding coronary artery vasomotion abnormalities. The book chiefly consists of two major parts, each of which explores the epidemiology, pathophysiology, diagnosis and treatment of the diseases. The chapters present a range of experimental and clinical studies, including the editor’s life’s work on coronary spasm; how Rho-kinase activation plays an important role in connection with the disease; how chronic adventitial inflammation is a central pathophysiology of the spasm; the importance of Rho-kinase activation in the pathogenesis of CMD; how epicardial spasm and CMD frequently co-exist; and much more. Coronary Vasomotion Abnormalities will help practicing cardiologists, cardiac surgeons, vascular biologists and radiologists understand the latest issues concerning the clinical, interventional, and surgical management of these conditions, and offer these readers valuable insights into the effective treatment of microvascular angina.

Mechanisms of Angiogenesis

Mechanisms of Angiogenesis
Author: Matthias Clauss
Publisher: Springer Science & Business Media
Total Pages: 342
Release: 2004-11-22
Genre: Medical
ISBN: 9783764364595

Is it advisable to go back from bedside to the bench? During the last decade, few topics encountered such a broad interest in bio- gy and medicine as angiogenesis. The amazing ability of the body to restore blood flow by induction of blood vessel growth as part of an adaptive process has alarmed physicians dealing with diseases in which angiogenesis is either exaggerated (as in tumors) or too slow (as in ischemic diseases of heart and brain). Not surprisingly, pro- and antiangiogenic strategies have found their way into clinical trials. For instance, for the USA, the NIH website in early 2004 displayed 38 clinical studies involving either pro- or antiangiogenic th- apies. Given the expected overwhelming wealth of clinical data, the question may be asked whether further exploration of biological mechanisms is required or whether results from the bedside are instructive enough to proceed. This question depends also on the progress of pro- and antiangiogenic clinical trials. In the following, I give a short overview about some of the progress that has been made in this field. Since Judah Folkman proposed antiangiogenic tumor therapy thirty years ago, it has become increasingly evident that agents which interfere with blood vessel formation also block tumor progression. Accordingly, antiangiogenic therapy has gained much attention as a potential adjunct to conventional c- cer therapy.